CliniQuantum

What CliniQuantum does

CliniQuantum is an Israel-based private technology company headquartered in Tel Aviv that has developed a quantum simulation platform aimed at clinical trial data analysis. The platform applies proprietary quantum Monte Carlo methods, accessed through an exclusive worldwide license from Quantum X Labs Ltd., to perform computational simulation and optimization of clinical trial datasets. The intended customer base comprises pharmaceutical and biotechnology companies and healthcare research institutions conducting or sponsoring clinical research.

The company's product surface consists of a single core platform rather than a multi-product portfolio, and there is no public evidence of a commercially launched, revenue-generating product as of the disclosed events. The underlying technology is quantum Monte Carlo computation rather than classical machine learning, positioning the offering as a computational simulation tool for trial design and analysis. No pricing model, contract structure, go-to-market channel, or commercial deployment milestones have been disclosed.

In June 2026, CliniQuantum was acquired by NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., for approximately 54% interest at a total consideration of roughly CAD$9.46 million plus up to US$2.5 million in earn-out. The acquisition followed a definitive agreement signed in March 2026 and was conditioned on TSX Venture Exchange and Israeli tax authority approvals. CliniQuantum continues to operate from Israel under the NeuroThera Labs umbrella, with its commercial trajectory now tied to SciSparc's broader strategic direction.

Name

CliniQuantum

Legal name

CliniQuantum Ltd.

Website

https://cliniquantum.com

Company type

Private

Operating status

Operating

Short description

CliniQuantum is an Israeli quantum technology company that offers a simulation platform for clinical trial data analysis using licensed quantum Monte Carlo methods, serving pharmaceutical, biotech, and healthcare research customers. It was acquired by NeuroThera Labs in 2026.

Ownership category

akta.pro rank

Product category

Clinical Trial Analytics Software

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand) (HDAGAEAB)

akta.pro secondary industry

Quantum Search & Sampling Algorithms (HDAGADAE)

Keywords

• Quantum computing
• Clinical trial analytics
• Quantum simulation
• Patient stratification
• Drug discovery

Headquarters

HQ city

Tel Aviv

HQ country

Israel

HQ region

Middle East

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations

Core offering

CliniQuantum provides a quantum simulation platform for clinical trial data analysis that uses proprietary quantum Monte Carlo sampling methods to identify patient subpopulations and hidden biological structures across molecular and patient data layers. The platform is built on an exclusive worldwide license from Quantum X Labs Ltd. for patented quantum Monte Carlo methods, enabling faster and more adaptive clinical studies with potentially fewer samples than traditional methods.

Product overview

CliniQuantum offers a single unified quantum simulation platform for clinical trial data analysis. The platform utilizes proprietary quantum Monte Carlo sampling methods under an exclusive worldwide license from Quantum X Labs Ltd. to identify hidden biological structures and non-linear dependencies across molecular and patient data layers, enabling pharmaceutical researchers to design more efficient clinical trials with potentially fewer samples required compared to traditional methods.

Differentiator

Problem solved

Functional benefit

Products and services

• Quantum Simulation Platform for Clinical Trial Data Analysis

Quantifiable outcome

• Potentially requires fewer samples than traditional clinical trial methods

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Quantum X Labs Ltd.coreOEM/ Whitelabel/ Licensing Partner · 4 June 2026CliniQuantum holds an exclusive worldwide license agreement with Quantum X Labs Ltd. to patented quantum Monte Carlo methods for identifying patient subpopulations in clinical trials. This exclusive license is the key asset of CliniQuantum, enabling the development of its quantum simulation platform for clinical trial data analysis.
• NeuroThera Labs Inc.coreStrategic or Co-development Partner · 4 June 2026NeuroThera Labs Inc., a majority-owned subsidiary of SciSparc Ltd., completed the acquisition of approximately 54% interest in CliniQuantum. The acquisition gives NeuroThera access to CliniQuantum's quantum computing platform designed to improve the efficiency of clinical trials through quantum simulation technology.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Emerging players

• Multiverse Computing: Multiverse Computing applies quantum and quantum-inspired algorithms to verticals including life sciences and pharmaceuticals, with portfolio offerings in molecular simulation and clinical/research optimization. It is an emerging peer to CliniQuantum in the niche of applied quantum algorithms for biopharma.
• Owkin: Owkin applies AI to clinical research and trial optimization, including patient stratification and outcome prediction for pharma/biotech sponsors. It is an emerging peer with overlapping use cases in advanced analytics for clinical trial design and patient subpopulation analysis.

Direct peers

• TriNetX: TriNetX operates a global health research network that identifies patient subpopulations and feasibility cohorts for clinical trials using real-world data analytics. It is a direct functional peer to CliniQuantum's patient subpopulation identification and trial design offering.
• Flatiron Health: Flatiron Health provides real-world clinical and molecular data analytics used to design and run oncology clinical trials, including patient cohort identification. It is a direct peer in the clinical trial data analysis and subpopulation analytics space that CliniQuantum targets.
• Xanadu Quantum Technologies: Xanadu builds quantum computing hardware and software, with a dedicated life sciences and drug discovery business applying quantum algorithms to pharma R&D. It directly parallels CliniQuantum's positioning as a quantum-algorithms-for-biotech platform serving pharmaceutical customers.

Broad incumbents

• Veeva Systems: Veeva is a leading cloud platform for the life sciences industry, providing clinical trial management, data, and analytics solutions used by global pharma. It is a broad incumbent that competes for the same pharma clinical operations budget that CliniQuantum would target.
• PsiQuantum: PsiQuantum is a well-capitalized quantum computing company pursuing fault-tolerant quantum systems with life sciences among its target applications. It is a broad incumbent that overlaps with CliniQuantum at the intersection of quantum computing and pharmaceutical/biotech R&D.
• Medidata Solutions: Medidata (a Dassault Systèmes company) is the dominant clinical trial technology platform, offering trial design, patient stratification, and analytics used by most major pharma sponsors. It is a broad incumbent alternative to CliniQuantum's clinical trial data analysis and patient subpopulation identification capabilities.
• Quantinuum: Quantinuum is a leading full-stack quantum computing company developing hardware, software, and algorithms with explicit life sciences and drug discovery applications. It is comparable to CliniQuantum as a much larger quantum platform pursuing pharmaceutical/biotech use cases, including molecular simulation and clinical research analytics.
• IBM Quantum: IBM Quantum is a major quantum computing platform with explicit healthcare and life sciences initiatives, including partnerships applying quantum methods to drug discovery and clinical research. It is a broad incumbent whose quantum-for-healthcare roadmap competes for the same customer mindshare CliniQuantum targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CliniQuantum